B cell non-Hodgkin's lymphoma: Rituximab safety experience

Arthritis Research and Therapy

Volumn 7, Issue SUPPL. 3, 2005, Pages

  Mohrbacher, Ann ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; HYDROCORTISONE; PARACETAMOL; PETHIDINE; PREDNISOLONE; RITUXIMAB; SODIUM CHLORIDE; VINCRISTINE;

ANEMIA; ANGIONEUROTIC EDEMA; ASTHENIA; B CELL LYMPHOMA; BRONCHOSPASM; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR RISK; CHILL; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERANCE; EPIDERMOLYSIS; FATIGUE; FLUSHING; FOLLOW UP; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPOTENSION; HYPOXIA; IMMUNOCYTOMA; INFECTION RISK; LARYNGITIS; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PARANEOPLASTIC SYNDROME; PARESTHESIA; PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RIGOR; RISK ASSESSMENT; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SURVIVAL TIME; THORAX PAIN; THROAT DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CLINICAL TRIALS; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 21644469786     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1739     Document Type: Review

References (13)

1. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
2. Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:4261-4267.
3. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
4. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
5. Davis TA, White CA, Grillo-López AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, et al.: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999, 17:1851-1857.
6. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, et al.: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
7. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network: Single agent rituximab as first-line and maintenance therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003, 21:1746-1751.
8. McLaughlin P, Hagemeister FB, Grillo-López AJ: Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999, Suppl 14:79-87.
9. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
10. Genentech Inc: Rituxan [Package Insert]. San Francisco, CA: Genentech Inc; 2004.
11. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin PC Jr, Bearden JD III, Richards P, Greco FA: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000, 95:3052-3056.
12. Ghielmini M, Schmitz SFH, Cogliatti S, Pichert G, Fey M, Bettiches D, et al.: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial [abstract]. Blood 2002, 100:604a.
13. Hainsworth JD, Litchy S, Greco FA: Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin's lymphoma (NHL) responding to single-agent rituximab: a randomized trial of the Minnie Pearl Cancer Research Network [abstract]. Blood 2003, 102:69a.